Classifying new anti-tuberculosis drugs: rationale and future perspectives

International Journal of Infectious Diseases

Volumn 56, Issue , 2017, Pages 181-184

  Tiberi, Simon ^a   Scardigli, Anna ^b   Centis, Rosella ^c   D'Ambrosio, Lia ^c,d   Muñoz Torrico, Marcela ^e   Salazar Lezama, Miguel Ángel ^e   Spanevello, Antonio ^f,g   Visca, Dina ^f   Zumla, Alimuddin ^h   Migliori, Giovanni Battista ^c   Caminero Luna, Jose A ^i,j  

^a BARTS HEALTH NHS TRUST   (United Kingdom)

^b TUBERCULOSIS AND MALARIA   (Switzerland)

^c Maugeri Care and Research Institute   (Italy)

^d Public Health Consulting Group SAGL   (Switzerland)

^e INSTITUTO NACIONAL DE ENFERMEDADES RESPIRATORIAS   (Mexico)

^f UNIVERSITY OF INSUBRIA   (Italy)

^g Care and Research Institute   (Italy)

^h UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

ⁱ HOSPITAL UNIVERSITARIO DE GRAN CANARIA DR NEGRÍN   (Spain)

^j INTERNATIONAL UNION AGAINST TUBERCULOSIS AND LUNG DISEASE   (France)

more..

Author keywords

Anti TB drugs; Bedaquiline; Delamanid; Fluoroquinolones; Linezolid; MDR XDR TB

Indexed keywords

AMIKACIN; AMINOSALICYLIC ACID; AMOXICILLIN; BEDAQUILINE; CAPREOMYCIN; CLAVULANIC ACID; CLOFAZIMINE; CYCLOSERINE; DELAMANID; ETHAMBUTOL; ETHIONAMIDE; GATIFLOXACIN; ISONIAZID; KANAMYCIN; LEVOFLOXACIN; LINEZOLID; MEROPENEM; MOXIFLOXACIN; PRETOMANID; PROTIONAMIDE; PYRAZINAMIDE; RIFABUTIN; RIFAMPICIN; SUTEZOLID; TEDIZOLID; TERIZIDONE; TUBERCULOSTATIC AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; DRUG CLASSIFICATION; DRUG EFFICACY; DRUG SAFETY; EVOLUTION; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; HUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; WORLD HEALTH ORGANIZATION; CLASSIFICATION; DRUG EFFECTS; DRUG MONITORING; MICROBIAL SENSITIVITY TEST; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

ANTITUBERCULAR AGENTS; BIOLOGICAL EVOLUTION; DRUG MONITORING; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT; WORLD HEALTH ORGANIZATION;

EID: 85009982262     PISSN: 12019712     EISSN: 18783511     Source Type: Journal    
DOI: 10.1016/j.ijid.2016.10.026     Document Type: Article

References (31)

1. 1 World Health Organization. WHO treatment guidelines for drug-resistant tuberculosis 2016 update. WHO/HTM/TB 2016.04. Geneva: WHO; 2016.
2. 2 Caminero, J.A., Scardigli, A., Classification of antituberculosis drugs: a new proposal based on the most recent evidence. Eur Respir J 46 (2015), 887–893.
3. 3 World Health Organization. Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. WHO/HTM/TB/2014.11. Geneva: WHO; 2014.
4. 4 Caminero, J.A., Sotgiu, G., Zumla, A., Migliori, G.B., Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis. Lancet Infect Dis 10 (2010), 621–629.
5. 5 ElMaraachli, W., Slater, M., Berrada, Z.L., Lin, S.Y., Catanzaro, A., Desmond, E., et al. Predicting differential rifamycin resistance in clinical Mycobacterium tuberculosis isolates by specific rpoB mutations. Int J Tuberc Lung Dis 19 (2015), 1222–1226.
6. 6 Caminero, J.A., Guidelines for clinical and operational management of drug-resistant tuberculosis. 2013, International Union Against Tuberculosis and Lung Disease, Paris, France.
7. 7 Caminero, J.A., Matteelli, A., Lange, C., Treatment of TB. Lange, C., Migliori, G.B., (eds.) Tuberculosis (ERS Monograph), 2012, European Respiratory Society, Sheffield, 154–166.
8. 8 Ahuja, S.D., Ashkin, D., Avendano, M., Banerjee, R., Bauer, M., Bayona, J.N., et al. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. PLoS Med, 9, 2012, e1001300.
9. 9 Falzon, D., Gandhi, N., Migliori, G.B., Sotgiu, G., Cox, H., Holtz, T.H., et al. Resistance to fluoroquinolones and second-line injectable drugs: impact on MDR-TB outcomes. Eur Respir J 42 (2013), 156–168.
10. 10 Migliori, G.B., Sotgiu, G., Gandhi, N.R., Falzon, D., De Riemer, K., Centis, R., et al. Collaborative Group for Meta-Analysis of Individual Patient Data in MDR-TB. Drug resistance beyond extensively drug-resistant tuberculosis: individual patient data meta-analysis. Eur Respir J 42 (2013), 169–179.
11. 11 Guglielmetti, L., Le Dû, D., Veziris, N., Caumes, E., Marigot-Outtandy, D., Yazdanpanah, Y., et al. Is bedaquiline as effective as fluoroquinolones in the treatment of multidrug-resistant tuberculosis?. Eur Respir J 48 (2016), 582–585.
12. 12 Sotgiu, G., Centis, R., D'Ambrosio, L., Alffenaar, J.W., Anger, H.A., Caminero, J.A., et al. Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis. Eur Respir J 40 (2012), 1430–1442.
13. 13 Sotgiu, G., Pontali, E., Migliori, G.B., Linezolid to treat MDR-/XDR-tuberculosis: available evidence and future scenarios. Eur Respir J 45 (2015), 25–29.
14. 14 Bolhuis, M.S., Tiberi, S., Sotgiu, G., De Lorenzo, S., Kosterink, J.G., van der Werf, T.S., et al. Linezolid tolerability in multidrug-resistant tuberculosis: a retrospective study. Eur Respir J 46 (2015), 1205–1207.
15. 15 Lewis, J.M., Hine, P., Walker, J., Khoo, S.H., Taegtmeyer, M., Squire, S.B., et al. First experience of effectiveness and safety of bedaquiline for 18 months within an optimised regimen for XDR-TB. Eur Respir J 47 (2016), 1581–1584.
16. 16 Tadolini, M., Lingtsang, R.D., Tiberi, S., Enwerem, M., D'Ambrosio, L., Sadutshang, T.D., et al. First case of extensively drug-resistant tuberculosis treated with both delamanid and bedaquiline. Eur Respir J 48 (2016), 935–938.
17. 17 Diacon, A.H., Dawson, R., Von Groote-Bidlingmaier, F., Symons, G., Venter, A., Donald, P.R., et al. Randomized dose-ranging study of the 14-day early bactericidal activity of bedaquiline (TMC207) in patients with sputum microscopy smear-positive pulmonary tuberculosis. Antimicrob Agents Chemother 57 (2013), 2199–2203.
18. 18 Diacon, A.H., Pym, A., Grobusch, M., Patientia, R., Rustomjee, R., Page-Shipp, L., et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med 360 (2009), 2397–2405.
19. 19 Diacon, A.H., Pym, A., Grobusch, M.P., de los Rios, J.M., Gotuzzo, E., Vasilyeva, I., et al. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N Engl J Med 371 (2014), 723–732.
20. 20 Pym, A.S., Diacon, A.H., Tang, S.J., Conradie, F., Danilovits, M., Chuchottaworn, C., et al. Bedaquiline in the treatment of multi- and extensively drug-resistant tuberculosis. Eur Respir J 47 (2016), 564–574.
21. 21 Tiberi, S., De Lorenzo, S., Centis, R., Viggiani, P., D'Ambrosio, L., Migliori, G.B., Bedaquiline in MDR/XDR-TB cases: first experience on compassionate use. Eur Respir J 43 (2014), 289–292.
22. 22 van Halsema, C., Humphreys, S., Bonington, A., Extensively drug-resistant tuberculosis: early access to bedaquiline for a UK patient. Eur Respir J 43 (2014), 292–294.
23. 23 World Health Organization. The use of bedaquiline in the treatment of multidrug-resistant tuberculosis: interim policy guidance. WHO/HTM/TB/2013.6. Geneva: WHO; 2013.
24. 24 Hartkoorn, R.C., Uplekar, S., Cole, S.T., Cross-resistance between clofazimine and bedaquiline through upregulation of MmpL5 in Mycobacterium tuberculosis. Antimicrob Agents Chemother 58 (2014), 2979–2981.
25. 25 Skripconoka, V., Danilovits, M., Pehme, L., Tomson, T., Skenders, G., Kummik, T., et al. Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis. Eur Respir J 41 (2013), 1393–1400.
26. 26 Wells, C.D., Gupta, R., Hittel, N., Geiter, L.J., Long-term mortality assessment of multidrug-resistant tuberculosis patients treated with delamanid. Eur Respir J 45 (2015), 1498–1501.
27. 27 World Health Organization. The use of delamanid in the treatment of multidrug-resistant tuberculosis. Interim policy guidance. WHO/HTM/TB2014.23. Geneva: WHO; 2014.
28. 28 Diacon, A.H., van der Merwe, L., Barnard, M., von Groote-Bidlingmaier, F., Lange, C., García-Basteiro, A.L., et al. β-Lactams against tuberculosis—new trick for an old dog?. N Engl J Med 375 (2016), 393–394.
29. 29 Sotgiu, G., D'Ambrosio, L., Centis, R., Tiberi, S., Esposito, S., Dore, S., et al. Carbapenems to treat multidrug and extensively drug-resistant tuberculosis: a systematic review. Int J Mol Sci, 17, 2016, 373.
30. 30 Tiberi, S., Sotgiu, G., D'Ambrosio, L., Centis, R., Arbex, M.A., Alarcon, A.E., et al. Comparison of effectiveness and safety of imipenem/clavulanate- versus meropenem/clavulanate-containing regimens in the treatment of multidrug and extensively drug-resistant tuberculosis. Eur Respir J 47 (2016), 1758–1766.
31. 31 Tiberi, S., D'Ambrosio, L., De Lorenzo, S., Viggiani, P., Centis, R., Sotgiu, G., et al. Ertapenem in the treatment of multidrug-resistant tuberculosis: first clinical experience. Eur Respir J 47 (2016), 333–336.